Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Advisors Vote Against Pfizer-BioNTech Booster Shot: Bloomberg

09/17/2021 | 03:33pm EDT


© MT Newswires 2021
All news about PFIZER, INC.
08:42aCDC approves Moderna, J&J COVID-19 boosters, mixing and matching doses
AQ
08:06aPFIZER : SA Surpasses 21 Million Administered Covid-19 Vaccine Doses
AQ
08:03aPFIZER : says COVID-19 vaccine more than 90% effective in kids
AQ
07:50aPFIZER : says COVID-19 vaccine more than 90% effective at protecting kids from infection, ..
AQ
02:00aEXPLAINER : Is it time to get a COVID-19 booster? Which one?
AQ
10/21Health Care Up As BioNTech Rallies -- Health Care Roundup
DJ
10/21New Zealand Ties Reopening to 90% Vaccination, Restrictions for Unvaccinated -- 2nd Upd..
DJ
10/21New Zealand Ties Reopening to 90% Vaccination, Restrictions for Unvaccinated -- Update
DJ
10/21New Zealand Ties Reopening to 90% Vaccination, Restrictions for Unvaccinated
DJ
10/21MODERNA : U.S. administers over 411 mln doses of COVID-19 vaccines - CDC
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 557 M - -
Net income 2021 18 627 M - -
Net Debt 2021 29 307 M - -
P/E ratio 2021 12,6x
Yield 2021 3,68%
Capitalization 240 B 240 B -
EV / Sales 2021 3,31x
EV / Sales 2022 3,77x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 42,86 $
Average target price 45,72 $
Spread / Average Target 6,68%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.16.27%240 303
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640
MERCK & CO., INC.-0.77%205 472